Further, a more direct evidence revealed that loss of heterozygosity (LOH) at B2M locus happened three folds higher in non-responders compared with responders from a cohort of melanoma patients treated with PD1 blockade (Sade-Feldman et al., 2017). The gene discussed is B2M; the disease is melanoma.